LUNG NON-SMALL CELL CARCINOMA

This study tests a drug called amivantamab, given as a shot under the skin, for people with advanced non-small cell lung cancer that has extra copies of the MET gene. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 88 participants will take par…

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 adults will receive the drug combination before their tumor is removed. The goal is to …

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow in a few new spots while on other treatments. The approach uses a PET scan to find the most active parts of the tumor and deliver a higher radi…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after lung cancer surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer coming back. About 1,210 participants will receive either the combi…

This study tests a new drug combination for people with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to the standard treatment osimertinib. The experimental drug, telisotuzumab vedotin, is designed to find and kill cancer cells that have…

This study tests whether adding two types of focused radiation (BgRT and SBRT) to the standard drug osimertinib can better control EGFR-positive non-small cell lung cancer that has started to grow in a few new spots. About 32 adults with advanced lung cancer will receive the comb…

This study tests whether giving the immunotherapy drug durvalumab after surgery can help prevent early-stage non-small cell lung cancer from returning. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be watched closely with no …

This study tests whether artificial intelligence (AI) can help doctors choose the right radiation dose for lung tumors. About 70 people with lung cancer or tumors that spread to the lung will receive precise, high-dose radiation (SBRT) with doses guided by an AI tool. The goal is…

This early-phase study tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose tumors stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Resea…

This early study tests whether adding low-dose IL-2 to the immunotherapy drug pembrolizumab can better activate the immune system against stage IV non-small cell lung cancer. About 15 people with untreated advanced lung cancer will receive the combination. The goal is to see if t…

This study tests a procedure called TACE (chemoembolization) for people with non-small cell lung cancer or lung tumors that have spread from other cancers. Doctors inject chemotherapy directly into the artery feeding the tumor, then block that artery with tiny beads. This traps t…

This study tests a special type of radiation called grid therapy combined with standard immunotherapy for people with stage IV non-small cell lung cancer that has gotten worse despite treatment. Grid therapy delivers high doses of radiation to small parts of the tumor, which may …

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it at the clinic. About 50 adults with various cancers will try both ways to see which they prefer and how it affects their quality of life. The goal is to reduce the time, cost, …

This study tests whether adding aerobic interval training (short bursts of intense exercise with rest periods) can improve immune activity and treatment response in 100 adults with non-small cell lung cancer who are already receiving immunotherapy. The goal is to see if exercise …

This study tests whether a yoga program designed for both patients and their family caregivers can improve physical function, fatigue, sleep, and quality of life. It includes 400 people with lung or esophageal cancer who are getting radiation therapy, plus their caregivers. Parti…

This study tests whether psilocybin, a substance from certain mushrooms, combined with talk therapy can safely help treat major depression in people with non-small cell lung cancer. Ten participants will receive the drug in a controlled setting and be monitored for side effects, …

This study is following 2000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue. No tre…

This study looks at two standard surgical techniques for removing early-stage lung cancer: tying off the vein first versus the artery first. The goal is to see which method better reduces the amount of tumor DNA that gets into the bloodstream during surgery. About 100 adults with…

This study looks at whether giving early-stage lung cancer patients information about quality of life outcomes helps them feel more satisfied with their choice between surgery and radiation therapy. About 150 adults with stage I or II lung cancer who are eligible for both treatme…

This study interviews 45 adults with non-small cell lung cancer who also had a past alcohol or substance use disorder. Researchers want to understand what helps or hinders these patients from getting cancer detection and treatment. The goal is to identify social barriers so docto…

This study looks at patients with non-small cell lung cancer who are getting chemotherapy, radiation, and immunotherapy. Researchers collect blood, stool, saliva, and lung function data to find early signs of lung inflammation (pneumonitis). The goal is to catch problems sooner a…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung, or genitour…

This study surveys 40 adults with non-small cell lung cancer who are already receiving immunotherapy. It aims to understand their satisfaction with current IV treatment and their interest in switching to a subcutaneous injection that could be given at home. The results will help …

This study looks at how biomarkers (like DNA from tumors in the blood) can help doctors predict which patients with advanced non-small cell lung cancer will respond to immunotherapy. It involves 535 participants and aims to use these markers to personalize treatment, especially w…

This study is testing whether a special communication tool helps doctors and lung cancer patients make treatment decisions together more effectively. The tool guides conversations about treatment options, benefits, and risks while considering each patient's personal situation and…